Project to Deliver Second Cell Line for Drug Candidate

CDMO Cobra Biologics has been contracted by Swedish biotechnology company Alligator Bioscience AB to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media.

In May 2015 Cobra released details of it’s involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase 1 trial in advanced solid tumours. During June, as a result of the company’s ‘exceptional achievements within the life-science industry’, Alligator won the coveted SwedenBIO Award 2016.

Peter Coleman, CEO Cobra Biologics, commented: “Cobra has been manufacturing protein therapeutics since 1995 and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality. I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs and would like to congratulate the team on their prestigious SwedenBIO Award.” 

Dr Per Norlén, CEO, Alligator Bioscience, commented: “Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system. We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program.”